Journals / Türk Kardiyoloji Derneği Arşivi / 2009 / Cilt: 37 - Sayı: 3

Oral anticoagulant use in patients with atrial fibrillation

Atriyal fibrilasyonlu hastalarda oral antikoagülan kullanımı

Pages
161–167
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The most important factor for inadequate oralanticoagulant use especially in patients having a high riskfor stroke is the low incidence of prescription of the drug bythe physicians, suggesting low influence of the guidelineson the clinical practice.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Oral anticoagulant therapy has been shown todecrease the risk for vascular complications in patients withatrial fibrillation (AF).
📊
Key Findings & Data:Study design: The study included 426 consecutive patients(256 women, 170 men; mean age 66±11 years) who presented with a diagnosis of AF between October 2007 andNovember 2008.
💡
Conclusion & Impact:Conclusion: The most important factor for inadequate oralanticoagulant use especially in patients having a high riskfor stroke is the low incidence of prescription of the drug bythe physicians, suggesting low influence of the guidelineson the clinical practice.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Oral anticoagulant therapy has been shown todecrease the risk for vascular complications in patients withatrial fibrillation (AF). We evaluated the frequency of oral anticoagulant use in patients with AF, whether oral anticoagulantuse was associated with effective INR values, and the reasons for not including an anticoagulant in the treatment. Study design: The study included 426 consecutive patients(256 women, 170 men; mean age 66±11 years) who presented with a diagnosis of AF between October 2007 andNovember 2008. The patients were inquired about whetherthey were using warfarin and/or aspirin and the reasons fornot taking an oral anticoagulant. The INR levels were measured in those receiving warfarin. Results: Permanent AF was present in 72.8%, and paroxysmal AF was present in 27.2%. Patients ≥75 years of ageaccounted for 32.4%. The risk for stroke was high in 69.3%,moderate in 21.8%, and low in 8.9%, hypertension being themost frequent risk factor (66.7%). Inquiry about medicationsshowed that 107 patients (25.1%) were taking aspirin andwarfarin, 21 patients (4.9%) and 237 patients (55.6%) weretaking warfarin and aspirin alone, respectively, while 61patients (14.3%) used none. The incidence of oral anticoagulant use was 30.1%, being significantly low in patients ≥75years of age (p=0.0001), and having hypertension (p=0.023)or coronary artery disease (p=0.004). Effective INR valuesrecommended by the guidelines were attained in 47.7%(n=61) of patients receiving warfarin. Sex, age, clinical riskfactors, and socioeconomic parameters were not associatedwith achievement of target INR values. The most frequentreason for not starting anticoagulant treatment was the lowtendency of physicians to prescribe the drug (74.3%), followed by the presence of contraindications (9.8%). Conclusion: The most important factor for inadequate oralanticoagulant use especially in patients having a high riskfor stroke is the low incidence of prescription of the drug bythe physicians, suggesting low influence of the guidelineson the clinical practice.

Özet

Amaç: Oral antikoagülan tedavinin atriyal fibrilasyonlu (AF) hastalarda vasküler olay riskini düşürdüğü gösterilmiştir. Bu çalışmada AF tanısı konmuş hastalarda oral antikoagülan tedavinin uygulanma sıklığı, oral antikoagülan tedavi görenlerin etkili INR değerlerine ulaşıp ulaşmadığı ve hastaların hangi nedenle oral antikoagülan ilaç kullanmadığı araştırıldı. Ça­lış­ma pla­nı: Çalışmada Ekim 2007- Kasım 2008 tarihleri arasında polikliniğimize AF tanısıyla başvuran ardışık 426 hasta (256 kadın, 170 erkek; ort. yaş 66±11) değerlendirildi. Hastaların warfarin ve/veya aspirin kullanıp kullanmadığı, oral antikoagülan kullanmıyorsa nedeni sorgulandı. Ayrıca, oral antikoagülan kullanan hastaların INR değerleri ölçüldü. Bul­gu­lar: Hastaların %72.8’inde sürekli/kalıcı AF, %27.2’sinde paroksismal AF vardı. Hastaların %32.4’ü 75 yaş ve üstü gruptaydı. İnme gelişim riski açısından hastaların %69.3’ü yüksek, %21.8’i orta, %8.9’u düşük risk grubundaydı. İnme açısından hipertansiyon (%66.7) en sık görülen risk faktörüydü. Hastaların 107’si (%25.1) aspirin ve warfarin, 21’i (%4.9) sadece warfarin, 237’si (%55.6) sadece aspirin kullanırken, 61 hasta (%14.3) hiçbirini kullanmamaktaydı. Oral antikoagülan kullanma oranı %30.1 bulundu. Yetmiş beş yaş ve üstü hastalarda (p=0.0001), hipertansiyon (p=0.023) ve koroner arter hastalığı (p=0.004) olanlarda oral antikoagülan kullanımı anlamlı derecede azdı. Oral antikoagülan kullanan hastaların %47.7’si (n=61) kılavuzların önerdiği hedef INR değerlerine ulaşabilmişti. Cinsiyet, yaş, klinik risk faktörleri ve sosyoekonomik parametrelerin hiçbiri hastaların hedef INR değerine ulaşmasında etkili bulunmadı. Oral antikoagülan kullanmama nedenleri arasında ilk sırada ilacın hekim tarafından reçetelendirilmemesi (%74.3), ikinci sırada tıbbi kontrendikasyonlar (%9.8) gelmekteydi. So­nuç: Özellikle inme riski yüksek olan AF’li hastalarda yetersiz oral antikoagülan kullanımının en önemli nedeninin hekimlerden kaynaklandığı görülmekte; bu durum kılavuzların klinik uygulamaya yeterince yansımadığını düşündürmektedir

🔖

Cite This Article

NAZLI, C., EREN, N. K., ACET, H., ERGENE, A. O., DUYGU, H., ERTAŞ, F. (2022). Oral anticoagulant use in patients with atrial fibrillation. Türk Kardiyoloji Derneği Arşivi, Cilt: 37 - Sayı: 3, 161–167. https://ajindex.com/articles/633415

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306:1018 22
  2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030
  3. Lévy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99:3028-35
  4. Yiğit Z (TAF Araştırıcıları adına). Türk Atriyal Fibrilasyon (TAF) Çalışması. Non-valvüler atriyal fibrilasyonlu hastalarda antikoagülan ve aspirinin tromboembolik risk üzerine etkilerinin karşılaştırıldığı çokmerkezli, randomize çalışma. Türk Kardiyol Dern Arş 2000;28:8-19
  5. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(1 Suppl):194S 206S
  6. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91
  7. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004; 43:929-35
  8. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1987;317:669-74
  9. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
  10. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-72
  11. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardio